[Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)].
Barthet
M
M
Brunet
P
P
Bernard
J C
JC
Dussol
B
B
Rodor
F
F
Jouglard
J
J
Berland
Y
Y
Sahel
J
J
D000208:Acute Disease; D000328:Adult; D000818:Animals; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D007893:Leishmania donovani / Q000302:isolation & purification; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000382:microbiology; D008536:Meglumine / Q000009:adverse effects* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced*
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate
Pancréatite aiguë au cours d'un traitement par l'antimoniate de méglumine (Glucantime).